The U.S. Food and Drug Administration (FDA) has launched a program letting eligible applicants request drug review files for use by foreign regulators, aiming to cut repeated assessments as products seek market access abroad.
Announced Nov. 17, the Global Reliance Disclosure Program (GRDP) gives applicants a way to obtain FDA approval packages with minimal redactions. The files contain the agency’s scientific analyses and regulatory assessments. Authorities abroad may consider those materials in their reviews, but each regulator makes its own marketing decision.
At launch, the program is limited to tentative approvals under the President’s Emergency Plan for AIDS Relief (PEPFAR), a U.S. initiative addressing HIV/AIDS worldwide. Products with tentative approval through abbreviated new drug applications (ANDAs) are excluded. The program’s Oct. 30 start coincided with a PEPFAR tentative approval for lenacapavir.
FDA guidance describes tentative approval as a finding that a drug meets statutory and regulatory requirements but cannot yet receive U.S. marketing approval because of patent or exclusivity protections. PEPFAR tentative approvals predate the GRDP; the guidance describes them as part of the FDA’s existing process for reviewing antiretroviral applications.
The participation window closes 10 calendar days after approval. Applicants also must affirm that a foreign marketing application is the intended use for the package. The FDA directs requests for other purposes to the Freedom of Information Act (FOIA) process.
The FDA says shortages of regulatory staff and resources can stretch national reviews to months or years, delaying access for patients. The agency presents file sharing as a way to reduce duplicated work, but it has not estimated the time that might be saved or specified who, if anyone, would bear costs.
For Jan. 2027, the FDA intends to add novel drugs filed through New Molecular Entity New Drug Applications and biologics covered by 351(a) Biologics License Applications. A separate pathway planned for early 2027 would allow requests for action packages covering drugs and biologics already approved or licensed in the United States.


